XENE Q3 2021 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+24.0% YoY

Gross Profit

-$11M-132.5% margin

Operating Income

-$16M-192.0% margin

Net Income

-$15M-190.1% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

+266.3%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$264M

Total Liabilities

$15M

Stockholders' Equity

$249M

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$7M	+24.0%
Gross Profit	-$11M	$7M	-264.3%
Operating Income	-$16M	-$10M	-60.8%
Net Income	-$15M	-$9M	-74.4%

Revenue Segments

License And Service

$3M100%